Format

Send to

Choose Destination
Br J Cancer. 2011 Oct 25;105(9):1342-5. doi: 10.1038/bjc.2011.402. Epub 2011 Oct 4.

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.

Author information

1
Department of Medical Oncology, Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada.

Abstract

BACKGROUND:

Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy.

METHODS:

The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1-2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer.

RESULTS:

There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ≤ 10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67 ≥ 25%) had oncotype RSs of high or intermediate risk.

CONCLUSION:

Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score.

PMID:
21970880
PMCID:
PMC3241562
DOI:
10.1038/bjc.2011.402
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center